Blueprint Medicines Overview
Blueprint Medicines (BPMC) has a P/E ratio of -120.99, below the Healthcare sector average of 25.9.
Get informed when a big investor buys or sells
+ Follow-120.99
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
As of the most recent data, BPMC shows a P/E ratio of -120.99. That is below the Healthcare sector average of 25.9. Scroll down for historical charts and peer comparison views.
The Healthcare sector average P/E ratio is about 25.9. Blueprint Medicines is at -120.99, which is lower that average. That is roughly 567.2% below the sector mean. Use the comparison chart on this page to see how BPMC stacks up against individual peers as well.
Investors watch BPMC's P/E ratio because it compresses price and fundamentals into one number that is easy to compare across companies and over time. Blueprint Medicines's latest reading is -120.99. Combining that with growth, ROE, and debt metrics usually beats relying on a single multiple.
Besides this p/e ratio page, Stockcircle has Blueprint Medicines's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect P/E ratio (currently -120.99) with ownership activity and broader fundamentals.
The Healthcare average P/E ratio is about 25.9, while BPMC is at -120.99. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.
